Colitis - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 94 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Colitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Colitis - Pipeline Review, H2 2014', provides an overview of the Colitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Colitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Colitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Colitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Colitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Colitis Overview 9
Therapeutics Development 10
Pipeline Products for Colitis - Overview 10
Pipeline Products for Colitis - Comparative Analysis 11
Colitis - Therapeutics under Development by Companies 12
Colitis - Therapeutics under Investigation by Universities/Institutes 14
Colitis - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Colitis - Products under Development by Companies 17
Colitis - Products under Investigation by Universities/Institutes 18
Colitis - Companies Involved in Therapeutics Development 19
Inovio Pharmaceuticals, Inc. 19
BioLineRx, Ltd. 20
Pfizer Inc. 21
Lpath, Inc. 22
Protalix BioTherapeutics, Inc. 23
Galapagos NV 24
Akebia Therapeutics, Inc. 25
NasVax Ltd. 26
Lycera Corp. 27
Zyngenia, Inc. 28
N30 Pharmaceuticals 29
Cognosci, Inc. 30
CellAct Pharma GmbH 31
GeneFrontier Corporation 32
Ajinomoto Pharmaceuticals Co., Ltd. 33
Prokarium Ltd. 34
Colitis - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
LT-1009 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
PF-06425090 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
etanercept biosimilar - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BL-5040 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VGX-1027 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
N-6022 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
filgotinib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
COG-112 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Anti-CD3 Oral Immunotherapy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
N-6547 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
LYC-30937 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CAP-2.1 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CAP-2.2 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
clostridium difficile vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Synthetic Peptides to Inhibit Panx1 for Colitis - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Monoclonal Antibody to Inhibit Ang-2 and TNF-a for Ulcerative Colitis and Inflammatory Disease - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NK-007 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Cell Therapy for Colitis - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Synthetic Peptide for Gastrointestinal, Respiratory and CNS Disorders - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Vaccine for Colitis and Respiratory Tract Inflammatory Disorders - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
APY-0201 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
GFC-101 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Vaccine for Colitis - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
AKB-6899 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RNAi Oligonucleotides to Inhibit TNFalpha for IBD and Colitis - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecule for Colitis - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
AcTMP-1 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
C-142 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Colitis - Recent Pipeline Updates 79
Colitis - Dormant Projects 88
Colitis - Product Development Milestones 90
Featured News & Press Releases 90
Mar 22, 2013: Lpath Receives Key European And US Patents Related To Anti-cancer Drug Program ASONEP 90
Mar 18, 2009: ViroPharma Submits Comments on Vancocin Draft Bioequivalence Guidance 91
Dec 18, 2008: ViroPharma Files FOIA Complaint Seeking Administrative Record for Vancocin 91
Dec 15, 2008: ViroPharma Provides Update on Vancocin 92
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 94
Disclaimer 94

List of Tables
Number of Products under Development for Colitis, H2 2014 10
Number of Products under Development for Colitis - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Colitis - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 19
Colitis - Pipeline by BioLineRx, Ltd., H2 2014 20
Colitis - Pipeline by Pfizer Inc., H2 2014 21
Colitis - Pipeline by Lpath, Inc., H2 2014 22
Colitis - Pipeline by Protalix BioTherapeutics, Inc., H2 2014 23
Colitis - Pipeline by Galapagos NV, H2 2014 24
Colitis - Pipeline by Akebia Therapeutics, Inc., H2 2014 25
Colitis - Pipeline by NasVax Ltd., H2 2014 26
Colitis - Pipeline by Lycera Corp., H2 2014 27
Colitis - Pipeline by Zyngenia, Inc., H2 2014 28
Colitis - Pipeline by N30 Pharmaceuticals, H2 2014 29
Colitis - Pipeline by Cognosci, Inc., H2 2014 30
Colitis - Pipeline by CellAct Pharma GmbH, H2 2014 31
Colitis - Pipeline by GeneFrontier Corporation, H2 2014 32
Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H2 2014 33
Colitis - Pipeline by Prokarium Ltd., H2 2014 34
Assessment by Monotherapy Products, H2 2014 35
Number of Products by Stage and Target, H2 2014 37
Number of Products by Stage and Mechanism of Action, H2 2014 39
Number of Products by Stage and Route of Administration, H2 2014 41
Number of Products by Stage and Molecule Type, H2 2014 43
Colitis Therapeutics - Recent Pipeline Updates, H2 2014 79
Colitis - Dormant Projects, H2 2014 88
Colitis - Dormant Projects (Contd..1), H2 2014 89